戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tive case management and skills training for relapse prevention.
2 s with schizophrenia that are independent of relapse prevention.
3 functioning, above and beyond the effects of relapse prevention.
4 as partially but not wholly mediated through relapse prevention.
5 in preclinical studies, could be relevant to relapse prevention.
6  have the highest confidence of evidence for relapse prevention.
7 ependent adults engaged in mindfulness-based relapse prevention.
8 erence in alcohol use decrease compared with relapse prevention.
9 ion amplify during abstinence and compromise relapse prevention.
10 represent a promising therapeutic target for relapse prevention.
11  objective screening, symptom management and relapse prevention.
12 re may thus be a selective new mechanism for relapse prevention.
13  all antipsychotics are equally effective in relapse prevention.
14 ed memories and has the potential to enhance relapse prevention.
15 e reactivity with potential implications for relapse prevention.
16 elated projection and a potential target for relapse prevention.
17 BNST PACAP systems may be viable targets for relapse prevention.
18 epresents a true challenge for treatment and relapse prevention.
19 ted with the greatest benefit with regard to relapse prevention.
20 g reduction, and maternal postpartum smoking relapse prevention.
21 lutamate receptor 2 should be considered for relapse prevention.
22 r CB1R as a potential therapeutic target for relapse prevention.
23 thium maintenance may be most beneficial for relapse prevention.
24 e)) is clinically used in many countries for relapse prevention.
25 mmunosuppression is the standard of care for relapse prevention.
26 f ongoing cocaine abuse but may be useful in relapse prevention.
27 control of infections, GVHD, engraftment and relapse prevention.
28  sleep hygiene, cognitive restructuring, and relapse prevention.
29 EC consisted of 3 family sessions focused on relapse prevention.
30 in may be a potential therapeutic target for relapse prevention.
31 en systematically assessed as a strategy for relapse prevention.
32 enia, negative symptoms, loss of insight and relapse prevention.
33 II mGluRs as promising treatment targets for relapse prevention.
34 itiated a 5-week course of mindfulness-based relapse prevention.
35 intaining long-term clinical response and in relapse prevention.
36 em to be particularly effective in promoting relapse prevention.
37 week to 92.65 [95% CI, 48.81-136.48] g/week; relapse prevention: 133.45 [95% CI, 93.71-173.19] g/week
38  33.84-40.96] to 13.18 [95% CI, 8.95-17.41]; relapse prevention: 39.09 [95% CI, 35.53-42.65] to 23.68
39 ptide (NOP) receptors will have utility as a relapse prevention agent for multiple types of drug abus
40  on maintaining long-term abstinence, making relapse prevention an essential therapeutic goal.
41                          This study compared relapse prevention and acceptability of long-acting inje
42 ect sizes and certainty of evidence for both relapse prevention and acceptability.
43 ess than 1.00 when compared with placebo for relapse prevention and almost all had 95% credible inter
44                               In addition to relapse prevention and psychiatric symptom relief, the b
45 Despite clear evidence for their efficacy in relapse prevention and symptom relief, their effect on s
46 ed to bupropion or placebo for 6 months (for relapse prevention) and smoking participants were eligib
47 therapy that addresses only substance abuse (relapse prevention) and with standard community care for
48 ite receiving fewer treatment sessions, less relapse prevention, and less continuous care.
49                           Seeking safety and relapse prevention are efficacious short-term treatments
50           In schizophrenia, effect sizes for relapse prevention are larger than for acute treatment.
51 ase in the integrated treatment arm than the relapse prevention arm (treatment-by-time interaction: F
52 signed to either the integrated treatment or relapse prevention arm.
53 a pharmacotherapeutic target for craving and relapse prevention associated with cocaine cue exposure.
54 ority of specific antipsychotics in terms of relapse prevention because most comparisons between anti
55  fluoxetine monotherapy may provide superior relapse-prevention benefit relative to lithium monothera
56 ly be seen as potential players not only for relapse prevention but also as candidate drugs for a fas
57                           Continuation-phase relapse-prevention CBT was effective in reducing the ris
58  retrieval-extinction procedure has superior relapse prevention characteristics than the CS memory re
59 e-blind, placebo-controlled, parallel-group, relapse-prevention clinical trial conducted in 10 commun
60 uential treatment strategy of fluoxetine and relapse-prevention cognitive-behavioral therapy (CBT) to
61 oderate to high GRADE certainty for superior relapse prevention compared with placebo was also found
62 clinician; motivational enhancement therapy; relapse prevention counseling; and on-site medical, addi
63                                     However, relapse prevention declined after 36 months, suggesting
64                                              Relapse prevention delayed time to first drug use at 6-m
65 ls that measured maternal postpartum smoking relapse prevention demonstrated a significant overall in
66  the first-line treatment when prescribing a relapse-prevention drug in patients with bipolar disorde
67 bo-controlled studies that have examined the relapse-prevention efficacy of maintenance therapy.
68 ychotic treatment may play a crucial role in relapse prevention, emphasizing the need for maintenance
69  social functioning, vocational recovery and relapse prevention; expert clinician and vocational supp
70 suggesting a need for frequent follow-up and relapse prevention-focused treatment during this period.
71 response curves for both acute treatment and relapse prevention follow a hyperbolic pattern, with max
72 erapy appears efficacious as a treatment for relapse prevention for those with recurrent depression,
73 s evaluated included contingency management, relapse prevention, general cognitive behavior therapy,
74 inence during induction were assigned to the relapse prevention group (20 individuals); otherwise, in
75                          Participants in the relapse prevention group had high abstinence (>80%; eg,
76 critical to allow better recovery and ensure relapse prevention in addicted subjects.
77 conclusion that CT specifically designed for relapse prevention in bipolar affective disorder is a us
78 he efficacy and acceptability of lithium for relapse prevention in bipolar disorder.
79  than monotherapy with either drug alone for relapse prevention in bipolar I disorder.
80 y and safety of olanzapine as monotherapy in relapse prevention in bipolar I disorder.
81 m to explore potential pharmacotherapies for relapse prevention in cocaine use disorder.
82 of heroin and may be useful as an adjunct to relapse prevention in detoxified opioid-dependent subjec
83 tor may be useful in the future treatment of relapse prevention in drug addiction through memory reco
84 dministered epigenetic enzyme inhibitors for relapse prevention in human drug users.
85           Even more effective strategies for relapse prevention in mood disorders are urgently needed
86 nancy, the benefits of lithium treatment for relapse prevention in psychiatric conditions must be wei
87                       Approaches as used for relapse prevention in psychosis or for chronic at-risk s
88                                              Relapse prevention in recurrent depression is a signific
89 gibility criteria typically used in RCTs for relapse prevention in schizophrenia spectrum disorders t
90 t-generation antipsychotics (FGAs) regarding relapse prevention in schizophrenia.
91 his article outlines a practical approach to relapse prevention in the primary care setting.
92     In this trial of integrated treatment vs relapse prevention, integrated treatment led to a greate
93                       We hypothesized that a relapse prevention intervention would improve adherence
94  and 87 met abstinence criteria to enter the relapse prevention intervention.
95 ice and a nurse-managed cognitive behavioral relapse-prevention intervention at bedside, with telepho
96                                              Relapse prevention is important, but it should be sustai
97                                   Given that relapse prevention is the most clinically challenging is
98 pment as analgesics, should be considered as relapse prevention maintenance treatment for opioid addi
99 ical findings suggest gene therapy targeting relapse prevention may be a potential therapeutic strate
100                            Mindfulness-based relapse prevention (MBRP), a group-based psychosocial af
101  indicate possible neurochemical targets for relapse-prevention medication.
102 herapy and 12-step facilitation, and alcohol relapse prevention medications.
103                                    Regarding relapse prevention, most of the 12 LAIs included outperf
104 assigned to integrated treatment (n = 45) or relapse prevention (n = 45).
105             Depression treatments, including relapse prevention, need to target these cognitive funct
106  particular, in posthospitalization care and relapse prevention of adult anorexia nervosa.
107 ns for diagnosis, safe and radical cure, and relapse prevention of Plasmodium Vivax.
108  anomaly) or efficacy (primary outcome, mood relapse prevention) of lithium treatment during pregnanc
109 ed, and on-demand coaching was initiated for relapse prevention; patients were instructed to continue
110 nd of nicotine patch therapy who entered the relapse prevention phase, 28% and 25% were not smoking a
111 Of the 61 patients who were eligible for the relapse prevention phase, 43 completed, with a mean redu
112  week for 2 weeks; and (iii) a symptom-based relapse prevention phase, whereby treatments were schedu
113 d on OFC throughout the study, including the relapse-prevention phase (up to 47 weeks).
114  abstinence at study week 52, the end of the relapse-prevention phase, confirmed by exhaled carbon mo
115         Sixty-one participants completed the relapse-prevention phase; 26 discontinued participation
116 ng of symptoms, and development of a written relapse prevention plan.
117                    Maintenance treatment and relapse-prevention planning (summarization of early warn
118 phone, addressed satisfaction with outcomes, relapse-prevention planning, self-monitoring, and social
119 primary care physicians were randomized to a relapse prevention program (n = 194) or usual primary ca
120                                            A relapse prevention program targeted to primary care pati
121    This study examined whether a program for relapse prevention (PRP) is more effective than treatmen
122 es social skills but has no clear effects on relapse prevention, psychopathology, or employment statu
123 mipramine hydrochloride combined with weekly relapse prevention psychotherapy.
124 based interventions and cognitive-behavioral relapse prevention (RP) approaches.
125 eks (TEL), twice-weekly cognitive-behavioral relapse prevention (RP), and twice-weekly standard group
126 e CB1R as a potential therapeutic target for relapse prevention.SIGNIFICANCE STATEMENT Drug relapse c
127 8) that emphasized motivational enhancement, relapse prevention, social skills training, and psychoed
128 al activation and cognitive restructuring to relapse prevention strategies, supported by telephonic s
129 ible individuals coupled with posttransplant relapse prevention strategies.
130 ng and/or after tapering may be an effective relapse prevention strategy instead of long-term use of
131 tudies were short term (</=4 months), and no relapse prevention studies or continuation phase studies
132 symptoms, concomitant medical illnesses, and relapse-prevention studies.
133    The authors report results from the first relapse prevention study in body dysmorphic disorder.
134      We believe this is the first controlled relapse-prevention study in subjects with TRD that suppo
135 rvention to provide effective vocational and relapse prevention support for young people with first-e
136 n, structured psychotherapy, and maintenance/relapse prevention support.
137                                    Regarding relapse prevention, the vast majority of the 31 included
138 ium has the strongest evidence for long-term relapse prevention; the evidence for anticonvulsants suc
139 f interest for the development of drug abuse relapse prevention therapies or antidepressants and othe
140                                              Relapse-prevention therapies attempt to interfere with d
141 lot ketamine combined with mindfulness-based relapse prevention therapy compared with ketamine and al
142                                              Relapse prevention therapy was provided directly to all
143 received seeking safety therapy, 34 received relapse prevention therapy, and 32 received standard com
144       All participants received twice-weekly relapse prevention therapy, provided observed urine samp
145 dium vivax malaria, has been associated with relapse prevention through the clearance of P. vivax par
146 tment has shifted from symptom reduction and relapse prevention to functional recovery; however, reco
147 ctive program provided direct monitoring and relapse prevention treatment for patients with ALD and w
148  outcome in women with anorexia nervosa in a relapse-prevention trial.
149                               Strategies for relapse prevention using primaquine are reviewed.
150 n treating alcoholism from the standpoint of relapse prevention using psychosocial interventions alon
151 economic evaluation, a CTR intervention with relapse prevention was likely to be cost-effective compa
152 istered with chloroquine for P vivax malaria relapse prevention was more efficacious than chloroquine
153 clear differences between antipsychotics for relapse prevention, we conclude that the choice of antip
154 ed responses could play an important role in relapse prevention, we examined whether baclofen-a GABAB
155 ivational enhancement; smoking cessation and relapse prevention; weight management counseling; and su
156 c telerehabilitation followed by 9 months of relapse prevention were compared with the cost-effective
157 isorders Using Prolonged Exposure [COPE]) or relapse prevention were delivered by trained and experie
158 behavioral activation, exposure therapy, and relapse prevention, with optional chapters on sleep and

 
Page Top